Abdul-Hay, M., Vale, C., Chan, O., Chandhok, N., DiNardo, C., Schiller, G., … Issa, G. (2025). Preliminary anti-leukemia activity from A phase 1 study of cln-049, a novel anti-FLT3 x anti-CD3 bispecific T-cell engager, in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and myelodysplastic syndrome (MDS). In Blood (Vol. 146, pp. 768–768). American Society of Hematology. https://doi.org/10.1182/blood-2025-768

Abdul-Hay, Maher, Colin Vale, Onyee Chan, Namrata Chandhok, Courtney DiNardo, Gary Schiller, Eunice Wang, et al. “Preliminary anti-leukemia activity from A phase 1 study of cln-049, a novel anti-FLT3 x anti-CD3 bispecific T-cell engager, in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and myelodysplastic syndrome (MDS).” In Blood, 146:768–768. American Society of Hematology, 2025. https://doi.org/10.1182/blood-2025-768.

Abdul-Hay M, Vale C, Chan O, Chandhok N, DiNardo C, Schiller G, et al. Preliminary anti-leukemia activity from A phase 1 study of cln-049, a novel anti-FLT3 x anti-CD3 bispecific T-cell engager, in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and myelodysplastic syndrome (MDS). In: Blood. American Society of Hematology; 2025. p. 768–768.

Abdul-Hay, Maher, et al. “Preliminary anti-leukemia activity from A phase 1 study of cln-049, a novel anti-FLT3 x anti-CD3 bispecific T-cell engager, in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and myelodysplastic syndrome (MDS).” Blood, vol. 146, no. Supplement 1, American Society of Hematology, 2025, pp. 768–768. Crossref, doi:10.1182/blood-2025-768.

Abdul-Hay M, Vale C, Chan O, Chandhok N, DiNardo C, Schiller G, Wang E, Hong S, Bachiashvili K, Chaudhry M, Kuplast-Barr K, Wu K, Shearer T, Hoang T, Shapiro I, Quigley M, Jones J, Blum W, Sallman D, Issa G. Preliminary anti-leukemia activity from A phase 1 study of cln-049, a novel anti-FLT3 x anti-CD3 bispecific T-cell engager, in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and myelodysplastic syndrome (MDS). Blood. American Society of Hematology; 2025. p. 768–768.